PCMA Calls for Expanding COVID-19 “Test to Treat” Protocols to Include Pharmacists

(Washington, D.C.) — Pharmaceutical Care Management Association (PCMA) President and CEO JC Scott today issued the following statement supporting the policy of one-stop COVID-19 testing and treatment at pharmacies and calling on the Biden Administration to expand the scope of its recently-announced “Test to Treat” program:

“We applaud the Biden administration on its efforts to increase access to medications that treat COVID-19 and respectfully request the Administration expand the “Test and Treat” program to allow pharmacists to prescribe anti-viral COVID-19 medications.

During the COVID-19 pandemic, pharmacy benefit managers have worked in collaboration with pharmacists by promoting rapid access to diagnostic tests, vaccines, and prescription drugs. By allowing more pharmacy sites to participate in the “Test and Treat” program, we could expand patient access to these treatments, helping to prevent hospitalization, serious disease, and further transmission.

We look forward to working with the pharmacy community and the Administration on implementation details for expanding the “Test and Treat” program in a safe and meaningful way and improving access to COVID-19 medications for all patients.”


PCMA is the national association representing America’s pharmacy benefit managers (PBMs).  PBMs administer prescription drug plans for more than 266 million Americans who have health insurance from a variety of sponsors including:  commercial health plans, self-insured employer plans, union plans, Medicare Part D plans, the Federal Employees Health Benefits Program (FEHBP), state government employee plans, Medicaid plans, and others.